Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma
Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Michele Maio(University of Siena), Elena Tornari(Ospedale Policlinico San Martino), Alessandro Testori(European Organisation for Research and Treatment of Cancer), Pier Francesco Ferrucci(MultiMedica), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Lorenza Di Guardo(Fondazione IRCCS Istituto Nazionale dei Tumori), Virginia Ferraresi(Cancer Institute (WIA)), Federica De Galitiis(Istituto Dermopatico dell'Immacolata), Antonio Maria Grimaldi(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Paolo Marchetti(Istituto Dermopatico dell'Immacolata), Jacopo Pigozzo(Istituto Oncologico Veneto), Carmen Nuzzo, Paola Queirolo, Riccardo Marconcini(Azienda Ospedaliera Universitaria Pisana), Gaetana Rinaldi(AOL (United States)), Luana Calabrò(University of Siena)
Cited by 157
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k